# Extranodal NK/T-Cell Lymphoma, Nasal Type, Presenting as an Isolated Oral Manifestation

**Authors:** Andrea Kanizsai, Ágnes Bán, László Kereskai, Árpád Szomor

PMC · DOI: 10.3390/dj14020129 · 2026-02-23

## TL;DR

A rare type of aggressive lymphoma presented as an oral lesion, mimicking other conditions and causing diagnostic delays.

## Contribution

This paper reports a rare case of extranodal NK/T-cell lymphoma presenting as an isolated oral lesion.

## Key findings

- The lesion mimicked benign or infectious conditions, leading to diagnostic delay.
- Histopathology and molecular analysis confirmed ENKTCL-NT with EBV positivity and TCRG rearrangement.
- Initial treatment showed partial response, but the disease eventually relapsed.

## Abstract

Background/Objectives: Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT), is a rare and extremely aggressive subtype of non-Hodgkin lymphoma that most frequently involves the nasal cavity and upper aerodigestive tract. Primary isolated oral manifestation is exceptionally uncommon and may mimic odontogenic or infectious diseases, delaying diagnosis. We report a case of ENKTCL-NT presenting initially as a destructive oral lesion without sinonasal involvement at diagnosis. Methods: A 32-year-old man with progressive palatal ulceration underwent clinical and imaging assessment (panoramic radiography and staging ^18F-FDG PET–CT) and repeated biopsies. Diagnosis was established using histopathology (H&E), immunohistochemistry (T-cell markers and cytotoxic profile), EBV detection by EBER in situ hybridization, and T-cell receptor gamma (TCRG) gene rearrangement analysis. Results: The lesion presented as a hemorrhagic, ulcerative palatal destruction covered by pseudomembranous exudate and was complicated by fungal infection, periostitis, and severe dental inflammatory foci, contributing to diagnostic delay. Histopathological examination revealed extensive necrosis with a dense atypical lymphoid infiltrate; angiocentric and angiodestructive growth was identified in one biopsy specimen. Tumor cells expressed T-cell markers (CD2, CD3, CD5, CD7; heterogeneous) and cytotoxic markers (TIA-1) and showed CD30 and CD56 positivity, with EBV positivity confirmed by EBER in situ hybridization. Molecular analysis demonstrated monoclonal TCRG rearrangement, and Ki-67 indicated high proliferative activity. Initial PET–CT demonstrated an intensely FDG-avid, locally invasive lesion without distant organ involvement. The patient was treated with L-asparaginase-based SMILE chemotherapy followed by radiotherapy (50 Gy), achieving marked initial clinical improvement and partial metabolic response; however, systemic relapse subsequently occurred with refractory disease despite salvage therapy and immunotherapy. Conclusions: This case highlights the substantial diagnostic challenge posed by isolated oral extranodal NK/T-cell lymphoma, nasal type, which may closely mimic benign inflammatory or infectious conditions and lead to significant diagnostic delay. Persistent, progressive, or therapy-resistant oral ulcerations should prompt early consideration of hematologic malignancy. Timely biopsy with comprehensive immunophenotyping, EBV testing, and close multidisciplinary collaboration are essential for accurate diagnosis and may contribute to earlier diagnosis and improved patient outcomes in these rare and atypical presentations.

## Linked entities

- **Genes:** TRG (T cell receptor gamma locus) [NCBI Gene 6965]
- **Proteins:** CD2 (CD2 molecule), cd.3 (Cd.3 conserved hypothetical protein), CD5 (CD5 molecule), CD7 (CD7 molecule), TIA1 (TIA1 cytotoxic granule associated RNA binding protein), TNFRSF8 (TNF receptor superfamily member 8), NCAM1 (neural cell adhesion molecule 1), Mki67 (antigen identified by monoclonal antibody Ki 67)
- **Diseases:** Extranodal NK/T-cell lymphoma, nasal type (MONDO:0019472), periostitis (MONDO:0004934)

## Full-text entities

- **Genes:** TRG (T cell receptor gamma locus) [NCBI Gene 6965] {aka TCRG, TRG@}, CD2 (CD2 molecule) [NCBI Gene 914] {aka LFA-2, SRBC, T11}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, TIA1 (TIA1 cytotoxic granule associated RNA binding protein) [NCBI Gene 7072] {aka ALS26, TIA-1, WDM}, VSIR (V-set immunoregulatory receptor) [NCBI Gene 64115] {aka B7-H5, B7H5, C10orf54, DD1alpha, Dies1, GI24}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, CD5 (CD5 molecule) [NCBI Gene 921] {aka LEU1, T1}, TNFRSF8 (TNF receptor superfamily member 8) [NCBI Gene 943] {aka CD30, D1S166E, Ki-1}, PAX5 (paired box 5) [NCBI Gene 5079] {aka ALL3, BSAP, PAX-5}, CD7 (CD7 molecule) [NCBI Gene 924] {aka GP40, LEU-9, TP41, Tp40}
- **Diseases:** lymphadenopathy (MESH:D008206), granulomatous disease (MESH:D006105), oral lesion (MESH:D009059), bleeding (MESH:D006470), ENKTCL-NT (MESH:D054391), dental neglect (MESH:D058069), odontogenic infection (MESH:D018126), ulcerative gingivitis (MESH:D005892), hematologic malignancies (MESH:D019337), facial pain (MESH:D005157), fever (MESH:D005334), midfacial disease (MESH:C537559), osteolytic (MESH:D030981), dental trauma (MESH:D014947), Periodontal swelling (MESH:D010518), chronic inflammation (MESH:D007249), EBV (MESH:D020031), oral ulcerations (MESH:D019226), painful (MESH:D010146), facial trauma (MESH:D020220), loss of consciousness (MESH:D014474), periostitis (MESH:D010522), lung cancer (MESH:D008175), T-cell lymphoid hyperplasia (MESH:D019310), Tumor (MESH:D009369), swelling (MESH:D004487), lymphoma (MESH:D008223), bacterial (MESH:D001424), EBV-associated lymphoproliferative disorders (MESH:D008232), non-Hodgkin lymphoma (MESH:D008228), Oral (MESH:D020820), destruction (MESH:D008105), fungal infection (MESH:D009181), Necrosis (MESH:D009336), oncologic (MESH:D000072716), periodontal disease (MESH:D010510), nasal obstruction (MESH:D015508), febrile neutropenia (MESH:D064147), infectious conditions (MESH:D003141), carious destruction (MESH:D003731), NK/T-cell lymphoma (MESH:D016399), dysphagia (MESH:D003680), infection (MESH:D007239), palatal (MESH:D002972), bone marrow infiltration (MESH:D001855), dental and (MESH:D009057), sinonasal disease (MESH:C535701), bone loss (MESH:D001847), odontogenic conditions (MESH:D009807), cytotoxic (MESH:D064420), weight loss (MESH:D015431), periostitis/osteitis (MESH:D010000), palatal or gingival destruction (MESH:D005891), mucocutaneous ulcer (MESH:D014456), hypovolemia (MESH:D020896)
- **Chemicals:** methotrexate (MESH:D008727), venetoclax (MESH:C579720), brentuximab vedotin (MESH:D000079963), ifosfamide (MESH:D007069), fluconazole (MESH:D015725), cytarabine (MESH:D003561), nivolumab (MESH:D000077594), CHOP (-), cisplatin (MESH:D002945), dexamethasone (MESH:D003907), etoposide (MESH:D005047), -FDG (MESH:D019788)
- **Species:** human gammaherpesvirus 4 (Epstein Barr virus, no rank) [taxon 10376], Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939484/full.md

---
Source: https://tomesphere.com/paper/PMC12939484